Luye submits NDA for schizophrenia, bipolar disorder therapy

Luye submitted an NDA to FDA for Rykindo risperidone extended-release microspheres (LY03004) to

Read the full 133 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE